Patent Overview
A research-oriented formulation dossier connected to hematologic and immune-system studies in local materials.
Indication: Research on Aplastic Anemia, Research on Hematological System Support, Research on Immune Mechanisms
Principle and Advantage
Shengxue Granules are most suitable for entering the 'Supportive Treatment Window for Aplastic Anemia and Bone Marrow Failure.' Its advantage lies not in consumer-oriented narratives, but in the fact that publicly available materials already contain research clues related to experiments, immunity, and blood parameters, which facilitates research-based collaboration packaging.
Scientific Basis: Combination of Macroscopic and Microscopic Syndrome Differentiation, Supporting and Nourishing the Root, Compilation of Hematological System-related Materials
- Can be presented as a 'Supportive Treatment Package for Rare Hematological Diseases' rather than a generic blood-tonifying formula page.
- Experimental research and mechanistic insights make it easier to enter the context of research collaborations.
- Suitable for presenting to partners as an early-stage asset with supporting literature, market potential, and a rationale rooted in rare diseases.
Market Context
Market reference：US annual diagnoses: 600–900; Promacta/Revolade FY2024 sales: USD 2.216B
- SAA remains a market dominated by transplantation and immunosuppression, leaving clear room for supportive assets to fill gaps.
- The rarity of the disease helps create clearer collaboration and differentiation narratives.
- With the entry of cell therapy and immunotherapy into this field, partners are more likely to accept the concept of 'combined assets' and supporting regimens.
Promacta / Revolade (eltrombopag)
Thrombopoietin receptor agonist · Used for severe aplastic anemia and other hematological indications, it is an important commercialized brand drug in this field.
Its sales volume provides a clear commercial benchmark for this area.
ATGAM
Equine anti-thymocyte globulin · Moderate to severe aplastic anemia, especially in patients who are not eligible for bone marrow transplantation.
Represents the classic immunosuppressive treatment pathway, indicating that standard therapy has not disappeared.
Omisirge
Cellular therapy · Cellular therapy pathway for severe aplastic anemia.
Marks a shift in this disease category from traditional immunosuppression toward higher-value treatment modalities.
Related Books
Research on Pei Zhengxue's Formulation Series
Research on Pei Zhengxue's Series of Formulas and Medicines / Compiled by Zhang Chouchou — Lanzhou: Gansu Science and Te.
Cooperation
Suitable as an entry point for research materials in the hematological field, facilitating mechanism discussions, organization of experimental data, and preliminary collaboration communications.
This page is for academic exchange and collaboration reference and does not constitute medical advice, product marketing, or efficacy claims.